hotspot -WSS

hotspot

author：hotspot 2025-09-30 20:46:56 - browse：2623

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration said Monday that it has deep reservations about NurOwn, an investigational ALS treatment from BrainStorm Cell Therapeutics, citing a lack of evidence that the medicine works and the company’s failure to demonstrate that it can properly manufacture the product.

In documents disclosed ahead of a Wednesday public hearing on NurOwn’s application for approval, the FDA detailed its problems with a clinical trial that missed its primary objective and noted that BrainStorm submitted “grossly deficient” information on how the medicine is made, voicing “major concerns that the available data do not meet the statutory standard of substantial evidence of effectiveness to support” approval.

BrainStorm filed for approval over the FDA’s protest, insisting that NurOwn has demonstrated benefits for a subset of ALS patients with milder disease. That conclusion, based on an after-the-fact analysis of the company’s failed pivotal trial, has proved polarizing among patients and physicians, with some arguing that the FDA should exercise flexibility in light of the irrevocably fatal nature of ALS and others demanding BrainStorm conduct another clinical trial to demonstrate its benefits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

hotspot

WSS

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

J&J expands global access to TB drug amid advocacy campaign

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Can CDC director Mandy Cohen drive consensus in Washington?

A new ‘biological computer' targets cancer while sparing healthy cells

Care demand spikes challenge UnitedHealth’s provider arm

entertainment

hotspot

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

'Golden Bachelor' Gerry Turner reveals what he wants in a partner and more

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why police arrested suspected Gilgo Beach killer away from his house

Sports medicine is finally prioritizing gender equality

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Dobbs anniversary: the lost opportunity of abortion as health care

Thousands of UK hospital doctors walk out in the latest pay dispute, crippling health services

BioMarin wins approval for gene therapy to treat hemophilia A

Telehealth startups are trying to fill the menopause care vacuum

explore

Federal judge rules Oregon’s tough new gun law is constitutional

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

The new HIV moral panic

Grail faces three suits alleging harassment, retaliation

Involuntary treatment for addiction doesn't work

Mystery swirls around US soldier who entered North Korea days ago, officials say

knowledge

hotspot

hotspot

focus